Breaking News Instant updates and real-time market news.

FISV

Fiserv

$84.39

(0.00%)

, TRIP

TripAdvisor

$60.38

(0.00%)

09:40
02/13/19
02/13
09:40
02/13/19
09:40

Unusually active option classes on open February 13th

Unusual total active option classes on open include: Fiserv (FISV), TripAdvisor (TRIP), Activision Blizzard (ATVI), Twilio (TWLO), Coty (COTY), Xilinx (XLNX), Gilead (GILD), FXI (FXI), Bristol Myers Squibb (BMY), and Nike (NKE).

FISV

Fiserv

$84.39

(0.00%)

TRIP

TripAdvisor

$60.38

(0.00%)

ATVI

Activision Blizzard

$41.68

(0.00%)

TWLO

Twilio

$115.38

(0.00%)

COTY

Coty

$10.87

(0.00%)

XLNX

Xilinx

$118.15

(0.00%)

GILD

Gilead

$65.40

(0.00%)

FXI

iShares China Large-Cap ETF

$42.60

(0.00%)

BMY

Bristol-Myers

$49.73

(0.00%)

NKE

Nike

$84.73

(0.00%)

  • 13

    Feb

  • 13

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 25

    Feb

  • 28

    Feb

  • 03

    Mar

  • 18

    Mar

  • 18

    May

  • 20

    May

FISV Fiserv
$84.39

(0.00%)

02/07/19
BTIG
02/07/19
DOWNGRADE
BTIG
Neutral
First Data downgraded to Neutral from Buy at BTIG
BTIG analyst Mark Palmer downgraded First Data (FDC) to Neutral while removing his price target of $28. The analyst notes that the accretion from the company's agreement to be acquired by Fiserv (FISV) has been reflected in the stock price, adding that he does not anticipate any additional bidders to emerge.
02/07/19
BUCK
02/07/19
INITIATION
Target $100
BUCK
Buy
Fiserv initiated with a Buy at Buckingham
Buckingham analyst Chris Brendler initiated Fiserv (FISV) with a Buy rating and a price target of $100, citing his deeper analysis of its First Data (FDC) deal. The analyst calls it a "transformational acquisition" that should lead to "compelling upside" in earnings and the stock price as a result from the companies' cross-sell opportunities and "considerable cost overlap". Brendler expects the market to revalue Fiserv shares as the benefits of the combination "become more evident".
02/13/19
02/13/19
DOWNGRADE
Target $25.5

Market Perform
First Data downgraded to Market Perform at Wells Fargo amid pending acquisition
As previously reported, Wells Fargo analyst Timothy Willi downgraded First Data (FDC) to Market Perform from Outperform to reflect the pending acquisition by Fiserv (FISV), which is expected to close during H2 2019. The analyst also lowered his price target on First Data's shares to $25.50 from $30 to reflect the exchange ratio and Fiserv's current share price of approximately $84.50.
02/07/19
02/07/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. XPO Logistics (XPO) initiated with a Buy at Loop Capital. 2. Spectrum (SPPI) initiated with an Overweight at Cantor Fitzgerald. 3. Fiserv (FISV) initiated with a Buy at Buckingham. 4. BRP Inc. (DOOO) initiated with a Hold at TD Securities. 5. Omega Healthcare (OHI) initiated with a Sector Perform at Scotiabank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TRIP TripAdvisor
$60.38

(0.00%)

01/31/19
VERF
01/31/19
INITIATION
VERF
Hold
TripAdvisor initiated with a Mixed at Vertical Group
02/13/19
PIPR
02/13/19
NO CHANGE
Target $58
PIPR
Neutral
TripAdvisor price target raised to $58 from $54 at Piper Jaffray
Piper Jaffray analyst Michael Olson raised his price target for TripAdvisor to $58 saying the company last night reported "solid" Q4 results with total revenue and EBITDA ahead of the Street. However, click-based and transaction revenue and Hotel revenue were both below expectations, while non-hotel segment revenue was ahead of consensus and accelerated growth to 38% year-over-year, Olson adds. He views TripAdvisor's 2019 guidance as in-line but notes the company expects headwinds in the first half of the year. The analyst keeps a Neutral rating on the shares.
01/09/19
JEFF
01/09/19
NO CHANGE
JEFF
Jefferies says be selective in Internet, cuts targets on Snap and Facebook
Jefferies analyst Brent Thill this morning cut his price targets on a handful of names in the Internet space. In a research note titled "2019 Playbook," the analyst also downgraded Booking Holdings (BKNG) and Redfin (RDFN) to Hold from Buy. Thill tells investors to selective in the space, and recommends buying Amazon.com (AMZN), Alphabet (GOOGL) and Intuit (INTU) in large cap, Match Group (MTCH), IAC (IAC) and GoDaddy (GDDY) in mid cap, and Wix.com (WIX) and Trade Desk (TTD) in small cap. He expects TripAdvisor (TRIP), Shutterstock (SSTK) and Shutterstock (EIGI) to underperform. Among his price target cuts were Buy-rated Expedia (EXPE) to $150, Buy-rated Facebook to $180, Hold-rated Snap (SNAP) to $7, Hold-rated Sonos (SONO) to $12, Hold-rated Twitter (TWTR) to $33 and Hold-rated Zillow Group (ZG) to $34.
01/04/19
GSCO
01/04/19
UPGRADE
Target $140
GSCO
Buy
Expedia upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Heath Terry upgraded Expedia (EXPE) to Buy and raised his price target for the shares to $140 from $125. While the analyst remains "generally cautious" on the travel space, he believes TripAdvisor (TRIP) and Booking's (BKNG) recent ad spend rationalization puts Expedia in a better relative position. He also thinks Expedia's "relatively low" trading multiple means it is likely to outperform in a tougher market environment for growth stocks. Terry views the stock as attractively valued at current levels.
ATVI Activision Blizzard
$41.68

(0.00%)

02/13/19
SPHN
02/13/19
NO CHANGE
Target $57
SPHN
Overweight
Activision Blizzard transition year creates buying opportunity, says Stephens
Stephens analyst Jeff Cohen noted that Activision Blizzard (ATVI), like peers Electronic Arts (EA) and Take-Two (TTWO), gave 2019 guidance that was significantly below consensus and framed it as a transition year. Cohen, who said he feels confident now is the time to be buying as 2019 should represent the trough of earnings power, lowered his price target on the shares to $57 from $65 but keeps an Overweight rating on Activision Blizzard shares.
02/13/19
JEFF
02/13/19
NO CHANGE
Target $75
JEFF
Buy
Activision Blizzard guidance enough given low expectations, says Jefferies
Reflecting the fact that Blizzard does not have a major front-line release in 2019, Activision Blizzard's 2019 earnings per share outlook of $2.10 is below Street at $2.50 but will be seen as enough to satisfy investors given very low expectations, Jefferies analyst Timothy O'Shea tells investors in a post-earnings research note. The analyst views current valuation levels as an attractive entry point and sees 2020 as the likely "payoff" from the transition year in 2019. He keeps a Buy rating on Activision Blizzard with a $75 price target.
02/13/19
KEYB
02/13/19
NO CHANGE
Target $57
KEYB
Overweight
Activision Blizzard price target lowered to $57 from $64 at KeyBanc
KeyBanc analyst Evan Wingren lowered his price target for Activision Blizzard to $57 from $64 following mixed results, and FY19 guidance below the sell-side consensus. However, given the negative reaction in stock year-to-date, the analyst believes this was anticipated. Wingren views the plan to increase development resources by 20% as positive, and believes a return to growth in revenue and EPS in FY20 is likely given a building pipeline and inflecting new business initiatives. He reiterates an Overweight rating on the shares.
02/13/19
FBCO
02/13/19
NO CHANGE
Target $64
FBCO
Outperform
Activision Blizzard price target lowered to $64 from $70 at Credit Suisse
Credit Suisse analyst Stephen Ju lowered his price target for Activision Blizzard to $64 from $70 following quarterly results. Given the usual 18-24 month game development cycles, the analyst is expecting revenue and free cash flow growth to return in 2020 but to a greater extent in 2021 as the company begins to reap the fruits of its investments and the release slate becomes more robust. Further, the analyst notes that 2019 initial guidance also seems appropriately conservative. He reiterates an Outperform rating on the shares.
TWLO Twilio
$115.38

(0.00%)

02/13/19
SPHN
02/13/19
NO CHANGE
SPHN
Equal Weight
Twilio expenses overshadow revenue beat, says Stephens
Stephens analyst Dmitry Netis said he believes Twilio shares could see some pressure at the open given the stock's 29% year-to-date run-up ahead of the company's report and the view that its higher than expected expenses may overshadow its strong revenue beat and guidance. The analyst, who said his estimates and price target are under review, keeps an Equal Weight rating on Twilio shares.
02/13/19
KEYB
02/13/19
NO CHANGE
Target $132
KEYB
Overweight
Twilio price target raised to $132 from $114 at KeyBanc
KeyBanc analyst Brent Bracelin raised his price target for Twilio to $132 from $114 on improving growth prospects. The analyst notes that the $19M revenue beat on a "staggering" growth rate of 77% year over year demonstrates the growth potential inherent in Twilio's consumption-based revenue model. He reiterates an Overweight rating on the shares.
02/13/19
DBAB
02/13/19
NO CHANGE
Target $130
DBAB
Buy
Twilio price target raised to $130 from $110 at Deutsche Bank
Deutsche Bank analyst Michael Turrin raised his price target for Twilio to $130 saying the company's Q4 results "showcase strength of this model." The analyst believes the outlook for 2019 looks good and he keeps a Buy rating on the shares.
02/13/19
DADA
02/13/19
NO CHANGE
Target $118
DADA
Buy
Twilio price target raised to $118 from $99 at DA Davidson
DA Davidson analyst Rishi Jaluria raised his price target on Twilio to $118 and kept his Buy rating after its Q4 results and FY19 guidance. The analyst notes that growth accelerated for the 4th consecutive quarter, while the company's lower than expected profitability guidance was related to its aggressive investment plans. Jaluria further cites Twilio's success with its Flex product, growth in its Uber related revenue, and its cross-selling potential of SendGrid.
COTY Coty
$10.87

(0.00%)

02/11/19
JPMS
02/11/19
NO CHANGE
Target $10
JPMS
Neutral
Coty price target raised to $10 from $7 at JPMorgan
JPMorgan analyst Andrea Teixeira raised her price target for Coty to $10 following the company's Q2 beat and keeps a Neutral rating on the shares. The analyst found "renewed energy from new management encouraging," but points out there there were "no major financial strings or timing attached to the turnaround at this point." Teixeira sees "massive execution risks" for the company, which keeps her on the sidelines post Friday's 32% "relief rally."
11/15/18
BMOC
11/15/18
UPGRADE
Target $12
BMOC
Outperform
Coty upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Shannon Coyne upgraded Coty to Outperform from Market Perform and kept her price target at $12. The analyst says that her downgrade in August was driven by concerns around the company's supply chain issues, but believes that these factors have now been fully priced in after the management withdrew its guidance and consensus earnings have been pulled back by about 30%. With a 30% decline in the stock price over the past 10 weeks, Coyne states that the risk-reward on shares of Coty is now "compelling".
11/15/18
11/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg saying the stock appears to be close to an inflection after several quarters of underperformance. 2. CopyTele (COPY) upgraded to Outperform from Market Perform at BMO Capital. 3. Voyager Therapeutics (VYGR) upgraded to Strong Buy from Outperform at Raymond James. 4. Athenex (ATNX) upgraded to Overweight from Neutral at JPMorgan with analyst Leon Chik saying more clinical data and progress in new drug trials should boost investor sentiment in 2019. 5. Coty (COTY) upgraded to Outperform from Market Perform at BMO Capital with analyst Shannon Coyne saying that her downgrade in August was driven by concerns around the company's supply chain issues, but believes that these factors have now been fully priced in after the management withdrew its guidance and consensus earnings have been pulled back by about 30%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/19
JPMS
01/04/19
UPGRADE
Target $7
JPMS
Neutral
Coty upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Andrea Teixeira upgraded Coty to Neutral with a $7 price target. The analyst's sum-of-the-parts analysis indicates Coty's valuation is "flushed out" at current levels. Teixeira, however, still sees potential downside to consensus estimates.
XLNX Xilinx
$118.15

(0.00%)

01/25/19
ARGS
01/25/19
NO CHANGE
Target $130
ARGS
Buy
Xilinx price target raised to $130 from $110 at Argus
Argus analyst Jim Kelleher raised his price target on Xilinx to $130 and kept his Buy rating, saying the company's Q3 results were strong and Q4 guidance "robust" just some of its semiconductor peers are posting negative comparisons and reducing expectations. The analyst notes that the end-market demand in communications is especially strong, with more carriers starting to build out their 5G infrastructure. While Xilinx has already "outperformed most semiconductor stocks amid tech-sector weakness", Kelleher believes that its "superior growth prospects" signal good value.
02/04/19
GSCO
02/04/19
DOWNGRADE
Target $122
GSCO
Buy
Xilinx downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Toshiya Hari removed Xlinx from the firm's Conviction List while maintaining a Buy rating, telling investors in a research note that the stock is up 51% since it was added to the Conviction List on January 5, 2018, during which the medium semiconductor stock under coverage was flat. Hari says he thinks Xilinx's favorable end-market exposure, growth opportunity in 5G and early traction in the data center market are now better understood by investors. Hari says his updated $122 price target implies 9% potential upside.
01/24/19
MKMP
01/24/19
NO CHANGE
Target $95
MKMP
Neutral
Xilinx price target raised to $95 from $85 at MKM Partners
MKM Partners analyst Ruben Roy raised his price target on Xilinx to $95 after its better than expected Q3 results showed broad-based strength across most end market segments. The analyst also notes the company's better than expected outlook for Q4 and believes that Xilinx is "benefiting from various new product and end market ramps as well as continued market share gains". Roy keeps his Neutral rating on the shares however, stating that the upside from the company's high medium-term expectations is priced in.
01/24/19
BMOC
01/24/19
NO CHANGE
Target $100
BMOC
Outperform
Xilinx price target raised to $100 from $90 at BMO Capital
BMO Capital analyst Ambrish Srivastava raised his price target on Xilinx to $100 and kept his Outperform rating after its Q3 earnings, saying the company "delivered on another quarter of solid results and guidance." The analyst notes that the company's wireless communications is "clearly helping as 5G deployments take hold", and also points to the strength of Xilinx's overall advanced product line-up. Srivastava further cites the company's operating margins remaining comfortably above 30% thanks to its operating expense discipline and top-line growth.
GILD Gilead
$65.40

(0.00%)

02/12/19
WBLR
02/12/19
NO CHANGE
WBLR
Viking could emerge as 'prime' buyout target for Gilead, says William Blair
Given Gilead Sciences' (GILD) leadership position in liver diseases and the significant resources that the company has devoted in the development of nonalcoholic steatohepatitis, last night's clinical setback "will likely reinvigorate" the company's willingness to augment its NASH pipeline, William Blair analyst Andy Hsieh tells investors in a research note. The analyst believes Gilead's Phase 3 failure could have a positive read-through to Viking Therapeutics (VKTX), which he notes is one of the only two beta-selective thyroid hormone receptor agonists in clinical testing. Viking's VK2809 demonstrated highly competitive data in reducing liver fat while maintaining a benign tolerability profile, Hsieh contends. Pending positive results from the company's Phase IIb study involving biopsy-confirmed NASH patients, he believes Viking Therapeutics "could emerge as a prime M&A target." The analyst keeps an Outperform rating on the shares. Viking in premarket trading is up 7% to $8.71.
02/12/19
02/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BHP Billiton (BHP) downgraded to Neutral from Buy at Goldman Sachs. 2. Gilead (GILD) downgraded to Neutral from Buy at Citi and to Market Perform from Outperform at Wells Fargo. 3. Cisco (CSCO) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst James Faucette saying Cisco's multiple has meaningfully expanded over the past 1.5 years as estimates and expectations have built in a likely benefit from security-driven networking. 4. Take-Two (TTWO) downgraded to Underperform from Market Perform at BMO Capital with analyst Gerrick Johnson saying that after a 2-year "hype machine" blast for its Red Dead Redemption 2 title and its "strong" premier, the buzz around the game has "dissipated markedly." 5. Fastenal (FAST) downgraded to Sector Weight from Overweight at KeyBanc with analyst Steve Barger saying he continues to view the company as a "best-in-class" distributor with a "sizable first-mover advantage" in OnSite and Vending, but he finds the stock's risk/reward as more balanced near his prior price target of $62. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/19
JPMS
02/12/19
NO CHANGE
JPMS
Overweight
Gilead failure in NASH not entirely surprising, says JPMorgan
The failure of Gilead Sciences' Phase 3 Stellar-4 study with selonsertib in nonalcoholic steatohepatitis is disappointing, albeit not entirely surprising, JPMorgan analyst Cory Kasimov tells investors in a research note. He points out that NASH never made it into his model, which leaves his estimates unchanged. However, the analyst thinks Gilead shares could still be off as much as 3%-5% on the failed trial "given the hit on sentiment and removal of pipeline optionality." The stock in premarket trading is down 4% to $65.00. Further, the negative development "may leave some with a bad taste" given management's positive tone on this data as recently as last week, Kasimov writes. He also thinks the NASH miss adds an increasing amount of pressure on the incoming CEO. The analyst keeps an Overweight rating on Gilead.
02/12/19
JEFF
02/12/19
NO CHANGE
Target $95
JEFF
Buy
Gilead shares will bounce back from NASH weakness, says Jefferies
Jefferies analyst Michael Yee expects shares of Gilead Sciences to be down "slightly" on the Phase 3 failure in nonalcoholic steatohepatitis but then "bounce as this is not the primary thesis." NASH represented a "call option" and expectations into the data were very low, Yee tells investors in a research note. The analyst, who does not expect the next selonsertib readout to work either, keeps a Buy rating on Gilead with a $95 price target. Last night's news removes a negative catalyst and "some investors may have even been waiting for this to pass," says Yee.
FXI iShares China Large-Cap ETF
$42.60

(0.00%)

BMY Bristol-Myers
$49.73

(0.00%)

02/11/19
GUGG
02/11/19
NO CHANGE
GUGG
Neutral
Patent ruling positive for Celgene and Bristol-Myers, says Guggenheim
Guggenheim analyst Seamus Fernandez said the Patent Trial and Appeal Board's decision denying Dr. Reddy's (RDY) inter partes review petition seeking to invalidate 3 Revlimid myelodysplastic syndrome patents expiring April 2023 is a positive for Celgene's (CELG) shareholders as well as for the combination with Bristol-Myers (BMY). Consistent with his below-consensus estimates for Revlimid, he continues to view a broad settlement, beginning with Dr. Reddy's, as the most likely outcome, Fernandez tells investors. He keeps a Neutral rating on Bristol-Myers shares.
01/23/19
MZHO
01/23/19
NO CHANGE
Target $81
MZHO
Buy
Mizuho sees 'significant upside' in Nektar shares, reiterates $81 price target
While shares of Nektar Therapeutics (NKTR) have performed strongly year-to-date, "significant upside remains," Mizuho analyst Difei Yang tells investors in a research note. A recent Nature article on IL-2 immunotherapy and new players in the field provide support for Nektar's approach to immuno-oncology, says Yang. Further, she believes the company's collaborations with large pharma, including Bristol-Myers Squibb (BMY) and Pfizer, underscore the "strong potential" of NKTR-214. With multiple data readouts expected in 2019, Yang sees "significant value" in Nektar shares. She reiterates a Buy rating on the name with an $81 price target. The stock closed yesterday down 3% to $44.76.
01/24/19
ADAM
01/24/19
NO CHANGE
Target $161
ADAM
Buy
Bluebird Bio's bb2121 'too valuable' for Bristol-Myers to share, says Canaccord
Assuming that the Bristol-Myers (BMY) and Celgene (CELG) transaction closes, Canaccord analyst John Newman said he expects Bristol-Myers will seek 100% control of bb2121 from Bluebird Bio (BLUE), calling the treatment "too valuable" to share due to the large long-term commercial potential and Bristol's deep expertise in commercialization. Stating that Bristol-Myers could try to acquire 100% control of bb2121 from Bluebird via a buyout, U.S. royalty, or higher EU royalty, Newman added that Bristol and Celgene do not have right of first refusal if an acquirer were to tender an offer, which he calls a "favorable setup" for Bluebird shareholders. The analyst, who estimates a Bluebird buyout to obtain the other half of the company could be valued at $8.8B-$10.5B, keeps a Buy rating and $161 price target on Bluebird Bio shares.
02/01/19
JEFF
02/01/19
DOWNGRADE
Target $95
JEFF
Hold
Celgene downgraded to Hold from Buy at Jefferies
Jefferies analyst Michael Yee reiterated his view that Bristol-Myers Squibb's (BMY) acquisition of Celgene (CELG) should continue on track and will likely close, though he noted that the spread has come in and that Celgene's comments on its earnings call suggest the potential for an earlier rather than later than expected closing of the deal. Yee keeps a $95 price target on Celgene shares, but downgrade the stock to Hold from Buy given that the upside he sees from current levels is less than 15%.
NKE Nike
$84.73

(0.00%)

01/25/19
JEFF
01/25/19
NO CHANGE
JEFF
Under Armour discounting down for tenth straight month, says Jefferies
Jefferies analyst Randal Konik says his firm's January webscrapes illustrate that Under Armour's (UAA) percentage of product on discount is down for the tenth month in a row year-over-year, while Adidas's (ADDYY) percentage is up for the eleventh month in a row. Further, Visits to Finish Line (FINL), Foot Locker (FL), and Under Armour websites reveal the HOVR, Project Rock, and Curry 6 are sold out in several sizes, indicating strong demand, Konik tells investors in a research note. He also believes that Nike (NKE) continues to dominate Adidas in running in the U.S.
01/25/19
JEFF
01/25/19
NO CHANGE
Target $67
JEFF
Buy
Foot Locker price target raised to $67 from $62 at Jefferies
Jefferies analyst Janine Stichter raised her price target for Foot Locker to $67 to reflect increased conviction that the company's business continues to gain momentum. Data the analyst looks at point to a Nike (NKE) resurgence in North America, "rising heat" around basketball and Jordans, a "healthy" innovation pipeline, and "controlled" promotions. The analyst still sees opportunity in Foot Locker shares despite the recent rally and keeps a Buy rating on the name.
01/24/19
MSCO
01/24/19
NO CHANGE
Target $103
MSCO
Overweight
Nike likely to gain most of Adidas' lost share, says Morgan Stanley
Noting that Morgan Stanley's European Brands analyst Elena Mariani believes the market is underestimating the cyclicality of Adidas' (ADDYY) business and downgraded the stock this morning to Underweight, Morgan Stanley analyst Lauren Cassel said she believes Adidas' recent slowdown can be directly linked to Nike's (NKE) aggressive comeback and "impressive innovation pipeline." Should Adidas face increasing sales pressure, Cassel would expect much of its share loss to be captured by Nike, she tells investors. The firm's Asia apparel/footwear OEMs analyst's channel checks suggest Adidas' footwear orders have been very volatile of late, which might reflect weakening end-demand. Meanwhile, the channel checks suggest the opposite for Nike, as they point to strong, consistent orders, Cassel said. She keeps an Overweight rating and $103 price target on Nike shares.
02/08/19
OPCO
02/08/19
NO CHANGE
Target $100
OPCO
Outperform
Nike price target raised to $100 from $90 at Oppenheimer
Oppenheimer analyst Brian Nagel raised his price target on Nike to $100 while reiterating it as a Top Pick, telling investors in a research note that he is "even more impressed" with the company's underlying operating prowess than he was after upgrading shares in October to Outperform. In addition to strong top-line dynamics, tighter inventory management globally continues to result in improved full price sell-through, unlocking margin upside in the Nike model, Nagel contends.

TODAY'S FREE FLY STORIES

WPM

Wheaton Precious Metals

$21.75

-0.26 (-1.18%)

17:12
02/21/19
02/21
17:12
02/21/19
17:12
Hot Stocks
Wheaton Precious Metals sees 365,000 ounces of gold produced in 2019 »

Wheaton's estimated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

17:10
02/21/19
02/21
17:10
02/21/19
17:10
Hot Stocks
Kraft Heinz says SEC probing procurement accounting policies »

The company said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

ACAM

Acamar Partners

$0.00

(0.00%)

17:10
02/21/19
02/21
17:10
02/21/19
17:10
Syndicate
Acamar Partners 30M share IPO priced at $10.00 »

Goldman Sachs and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMH

American Homes 4 Rent

$22.79

0.11 (0.49%)

17:07
02/21/19
02/21
17:07
02/21/19
17:07
Earnings
Breaking Earnings news story on American Homes 4 Rent »

American Homes 4 Rent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AMH

American Homes 4 Rent

$22.79

0.11 (0.49%)

17:06
02/21/19
02/21
17:06
02/21/19
17:06
Earnings
American Homes 4 Rent reports Q4 AFFO 25c, consensus 28c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

LPLA

LPL Financial

$76.68

-0.87 (-1.12%)

17:06
02/21/19
02/21
17:06
02/21/19
17:06
Hot Stocks
LPL Financial reports total brokerage, advisory assets at January-end up 5.2% »

Total brokerage and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

OMF

OneMain Holdings

$34.09

-0.45 (-1.30%)

17:05
02/21/19
02/21
17:05
02/21/19
17:05
Initiation
OneMain Holdings initiated  »

OneMain Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 14

    Mar

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

17:04
02/21/19
02/21
17:04
02/21/19
17:04
Hot Stocks
Breaking Hot Stocks news story on Kraft Heinz »

Kraft Heinz slips 8.8%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

EVRG

Evergy

$59.86

0.45 (0.76%)

17:02
02/21/19
02/21
17:02
02/21/19
17:02
Earnings
Breaking Earnings news story on Evergy »

Evergy reports Q4 pro…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

17:02
02/21/19
02/21
17:02
02/21/19
17:02
Earnings
Kraft Heinz reports Q4 adjusted EPS 84c, consensus 94c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

GNMK

GenMark

$6.82

0.11 (1.64%)

17:02
02/21/19
02/21
17:02
02/21/19
17:02
Hot Stocks
GenMark promotes Johnny Ek to CFO »

GenMark Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 06

    Mar

MFIN

Medallion Financial

$5.96

0.14 (2.41%)

17:01
02/21/19
02/21
17:01
02/21/19
17:01
Initiation
Medallion Financial initiated  »

Medallion Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

OTTW

Ottawa Bancorp

$13.55

(0.00%)

17:00
02/21/19
02/21
17:00
02/21/19
17:00
Hot Stocks
Ottawa Bancorp raises quarterly dividend to 6c per share from 5c »

Ottawa Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$27.25

-0.46 (-1.66%)

17:00
02/21/19
02/21
17:00
02/21/19
17:00
Initiation
Regional Management initiated  »

Regional Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ED

Consolidated Edison

$80.00

1 (1.27%)

16:59
02/21/19
02/21
16:59
02/21/19
16:59
Earnings
Breaking Earnings news story on Consolidated Edison »

Consolidated Edison sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

ED

Consolidated Edison

$80.00

1 (1.27%)

16:59
02/21/19
02/21
16:59
02/21/19
16:59
Earnings
Consolidated Edison reports Q4 EPS 77c, consensus 75c »

"We had a strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

OPNT

Opiant Pharmaceuticals

$14.65

-0.25 (-1.68%)

16:57
02/21/19
02/21
16:57
02/21/19
16:57
Hot Stocks
Breaking Hot Stocks news story on Opiant Pharmaceuticals »

Opiant down 11.3% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AL

Air Lease

$37.73

-0.59 (-1.54%)

16:57
02/21/19
02/21
16:57
02/21/19
16:57
Earnings
Breaking Earnings news story on Air Lease »

Air Lease reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SWM

Schweitzer-Mauduit

$34.69

-0.19 (-0.54%)

16:56
02/21/19
02/21
16:56
02/21/19
16:56
Earnings
Breaking Earnings news story on Schweitzer-Mauduit »

Schweitzer-Mauduit sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Mar

CZR

Caesars

$9.42

-0.21 (-2.18%)

16:56
02/21/19
02/21
16:56
02/21/19
16:56
Hot Stocks
Caesars CEO Frissora to remain in role until April 30 »

On November 1, 2018, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SWM

Schweitzer-Mauduit

$34.69

-0.19 (-0.54%)

16:56
02/21/19
02/21
16:56
02/21/19
16:56
Earnings
Schweitzer-Mauduit reports Q4 EPS 90c, consensus 71c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Mar

CZR

Caesars

$9.42

-0.21 (-2.18%)

16:54
02/21/19
02/21
16:54
02/21/19
16:54
Hot Stocks
Caesars CEO says financial priority is to 'further de-lever the balance sheet' »

"In 2018, Caesars…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

IQ

iQIYI

$22.76

0.17 (0.75%)

16:53
02/21/19
02/21
16:53
02/21/19
16:53
Earnings
iQIYI sees Q1 revenue $989.6M-$1B, consensus 972.94M »

For the first quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 20

    Mar

CZR

Caesars

$9.42

-0.21 (-2.18%)

16:52
02/21/19
02/21
16:52
02/21/19
16:52
Hot Stocks
Caesars reports Q4 Enterprise-wide adjusted EBITDAR increased 12.1% »

Enterprise-wide fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

IQ

iQIYI

$22.76

0.17 (0.75%)

16:51
02/21/19
02/21
16:51
02/21/19
16:51
Earnings
iQIYI reports Q4 EPS (70c), consensus (71c) »

Reports Q4 revenue $1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 20

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.